Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
abandoned, abrocitinib, adjudicated, adjudication, akcea, amlodipine, antisense, attachment, BEACON, bidder, binimetinib, Braftovi, broad, cap, CDI, Chapel, checkpoint, CHMP, clearance, College, confidential, conveyed, copay, copy, creativity, Creek, database, demerger, derecognized, encorafenib, Fabre, FCPA, Glenmark, globulin, heart, Hill, hip, HIPAA, immunosuppression, incidence, infection, Inquiry, introduction, JV, Kit, knee, Likewise, LLP, locked, lymphoproliferative, Mektovi, metabolic, Missouri, NaN, Neulasta, nonsteroidal, OA, Octagam, Panzyga, pegfilgrastim, percent, pharmacovigilance, Pierre, polyneuropathy, PRAC, principle, procedure, qualification, Relpax, Rodino, Russian, Sanford, SC, slightly, superseded, tied, tumor, unamortized, uncertainty, unvested, urgency, Utah, VBP, viii
Filing tables
Filing exhibits
Related press release
Associated PFE transcripts
PFE similar filings
Filing view
External links